Easton Pharma’s Oxazepam Receives NMPA Approval and Partners with Nhwa
Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval...
Deals
Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products
US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...
BioAge Labs Partners with JiKang for APJ Agonist Nanobody License
US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...
Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer
Sainte Nutritional Inc., China’s leading provider of Food for Special Medical Purpose (FSMP), has filed...
Harbin Gloria Partners with Eisai to Promote Methycobal in China
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has entered into a market promotion service...
Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline
French pharmaceutical giant Sanofi (NASDAQ: SNY) announced plans to acquire US-based Blueprint Medicines Corporation for...
BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors
Germany-based BioNTech SE (NASDAQ: BNTX) announced a strategic partnership with US major Bristol-Myers Squibb (BMS,...
Harbin Pharma Agrees to Acquire Clinical Approval for Jesduvroq from Bocimed
China’s Harbin Pharmaceutical Group Holding Co., Ltd (SHA: 600664) announced a technology transfer agreement with...
Hansoh Pharmaceutical Partners with Regeneron for HS-20094 Global Rights
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with Regeneron Pharmaceuticals...
LongBio Pharma Secures RMB 200 Million Series C Funding for Clinical Studies
China-based LongBio Pharma, a developer of biomacromolecule drugs, has reportedly raised over RMB 200 million...
Neowise Biotech Licenses TCR Molecule to BeOne Medicines for Next-Gen Cell Therapy
Suzhou-based Neowise Biotechnology, a specialist in T Cell Receptor (TCR)-based therapies for solid tumors, announced...
Nurix Therapeutics Announces Sanofi’s Acquisition of STAT6 Program Rights
US-based Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced that Sanofi (NASDAQ: SNY), a major French pharmaceutical...
Hanx Bio Files for Hong Kong IPO with ICBC International as Sole Sponsor
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing...
Shanghai Ark Bio and Partex Collaborate on ATR Inhibitor AK0658 Development
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based...
MicroPort CardioFlow to Acquire 49% Stake in La Ronda for RMB 171 Million
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...
Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development
Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...
Danaher Partners with AstraZeneca to Advance Precision Medicine
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...
Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship
China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...
GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation
Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD...